bitFlyer Makes Cryptocurrency Trading Even Easier with Launch of bitFlyer App
21.10.2019 08:00:00 EEST | Business Wire | Press release
Today, leading cryptocurrency exchange bitFlyer has announced the launch of the bitFlyer app across Europe and the USA. The app, available for free on both iOS and Android, will allow users to buy and sell Bitcoin (BTC), Ethereum (ETH), Litecoin (LTC), Bitcoin Cash (BCH), Ethereum Classic (ETC), Monacoin (MONA) and Lisk (LSK).1
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191020005009/en/
bitFlyer app iOS
The bitFlyer app will make it even easier for users to buy and sell, whilst still adhering to the same robust KYC and verification standards as the bitFlyer website.
Since 2014, bitFlyer has been trusted by millions across the globe as the most secure platform to easily buy and sell cryptocurrencies, and remains the only exchange licensed to operate across the US, Japan and Europe combined. This app launch is the latest development in a major growth strategy by the European and US businesses, to match what is already available to millions of bitFlyer Japan customers, where bitFlyer is recognised as a household name and one of the longest-standing cryptocurrency exchanges.
Yuzo Kano, bitFlyer founder and CEO of bitFlyer USA, said: “With the new bitFlyer apps, we are bringing the reliability, security and experience of Japan's market leader to our European and American customers, closing the gap between our service offerings and creating a truly global and regulated exchange product.”
Andy Bryant, Co-head and COO at bitFlyer Europe, said: “With our Buy/Sell platform, we strived to create a simpler, faster and even more transparent experience where everyone can buy cryptocurrencies in just a few minutes and from a reputable source. Now with the bitFlyer app, this is even more convenient for users.
We are staying true to our mission of making the world simpler with blockchain, by making the transparency, security and simplicity of our robust trading platforms available via a quick, single app download.”
Buy instantly and securely
The bitFlyer app was created with users in mind, making it even easier for those who prefer navigating from a smartphone to buy and sell cryptocurrencies. Current bitFlyer users can log on to the app with their existing account details, while new traders can register by using an email address, and inputting the relevant information for KYC procedures to deposit and begin trading.
Other features of the bitFlyer app include:
● Users are shown real-time price data, notified about the latest market movements and given access to the latest cryptocurrency news without leaving the app, encouraging users to always stay on top of the market and make informed decisions
● Users can clearly follow their position, making it even easier to keep track of profit and loss (PnL), view trade history and seamlessly visualise their portfolio
● Users can now simply scan a QR code to send and receive virtual currencies with bitFlyer
● From October 21st to October 27th, new customers downloading the bitFlyer app and registering a new verified account will receive €10 (or $10 if based in the US) in BTC without any deposit required.
Key features:
● Buy Bitcoin, Ethereum, Litecoin and more in just a few taps using USD, EUR, or JPY 2
● See real-time price data and get notified about market movements
● Added news functionality allows users to access the latest industry news without leaving the app
bitFlyer launched in the USA in November 2017, followed by bitFlyer Europe in January 2018, both as fully owned subsidiaries of bitFlyer, Inc., a household name in the cryptocurrency space in Japan and one of the longest-standing cryptocurrency exchanges. It is the only cryptocurrency exchange to be licenced in Japan, the US and Europe combined, and has also recently been recognised as one of only 10 exchanges that isn’t faking trading volumes.
bitFlyer is passionate about the future of the cryptocurrency industry and aims to support that future by setting the global standard for exchanges. It believes that standards and regulations are fundamental to the future of the industry and is often involved in conversations at the highest level, including having taken part in the recent G20 discussions. It was also involved in the amendment to the Payments Act in Japan which famously recognised bitcoin as legal tender.
The company continues to build out its product portfolio in line with its vision to break down barriers of entry that many face while accessing cryptocurrency. bitFlyer Japan already offers a wide range of products, and the addition of new Apps in the US and EU is the beginning of the brand’s ambition to expand access to cryptocurrency on a global scale.
ENDS
About bitFlyer EUROPE S.A.
bitFlyer EUROPE S.A. is a wholly-owned subsidiary of bitFlyer, Inc., a leading bitcoin and blockchain company based in Japan. The European office is located in Luxembourg and operates an exchange platform for European traders to buy and sell cryptocurrencies. bitFlyer EUROPE S.A. site: https://bitflyer.com/en-eu/
About bitFlyer USA, Inc.
bitFlyer USA, Inc. is a wholly-owned subsidiary of bitFlyer, Inc., a leading Bitcoin and blockchain company based in Japan. The US office is located in San Francisco and operates an exchange platform for US traders to buy and sell cryptocurrencies. Launching in the U.S. in 2017, bitFlyer USA currently operates in 46 states and territories, including New York as a holder of the New York Bitlicense. bitFlyer USA, Inc., site: https://bitflyer.com/en-us/
1MONA and LSK available in Europe and Japan only.
2 Depending on jurisdiction
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191020005009/en/
Contact information
Lauren Armour
Tyto PR
07826 557 326
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Wyss Geneva Steps Into Its Next Chapter11.6.2026 14:33:00 EEST | Press release
The Wyss Center for Bio and Neuroengineering in Geneva is pleased to announce the appointment of Dr. Tracy Laabs as Director, effective July 1st 2026. Dr. Laabs succeeds Prof. Dr. Erwin Böttinger, who leaves behind a fundamentally transformed organization: one that no longer just pursues breakthrough science but systematically turns it into ventures that reach patients. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260611328520/en/ Dr. Tracy Laabs, incoming Director, Wyss Center Geneva Since joining the Wyss Center as Director in April 2023, Prof. Böttinger brought a bold vision: to evolve the Center from a portfolio of promising projects into a disciplined engine for venture creation. Under his leadership, the Center spun off six companies in two years (including ABILITY Neurotech SA and Clee Medical SA in 2025) while simultaneously building a robust pipeline of next-generation programs in AI-guided neuromodulation and min
BeOne Showcases Landmark Phase 3 Data in CLL Patients Aged 80+ at EHA 2026, Reinforcing BRUKINSA Benefit11.6.2026 14:24:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced the presentation of a large Phase 3 dataset in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) aged 80 and older, showing sustained benefit with BRUKINSA after nearly 6.5 years of follow-up, reinforcing its role as the foundational BTK inhibitor. BRUKINSA is the only BTK inhibitor to demonstrate superior efficacy vs. ibrutinib in a Phase 3 trial.1 These data, one of the largest datasets of older patients with treatment-naive CLL, will be presented at the 2026 European Hematology Association (EHA) Congress in Stockholm, Sweden. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: "While the median age of diagnosis for CLL is 70 and the average age of treatment initiation is 75, many pivotal trials still underrepresent the patients that physicians most often see in practice. These data show that the durable benefit of
Clearlake Expands Liquid Credit Platform With Acquisition of LCM Asset Management’s CLO Contracts11.6.2026 14:00:00 EEST | Press release
Clearlake Capital Group, L.P. (“Clearlake” or the “Firm”), a global investment firm managing integrated platforms spanning private equity, liquid and private credit, and other related strategies, today announced that its credit platform, Clearlake Credit, will assume management of CLOs managed by LCM Asset Management, LLC. The transaction adds 31 CLOs representing more than $5 billion of assets under management and increases assets managed by Clearlake Credit to approximately $39 billion across liquid credit, private credit, and other customized credit solutions. The acquisition further broadens the Firm’s capabilities, deepens its relationships with institutional investors, and reinforces its client-centric approach and commitment to seeking attractive risk-adjusted returns across market cycles. Milbank LLP and Dechert LLP represented Clearlake Credit in the transaction. GreensLedge Capital Markets advised the seller. About Clearlake Clearlake Capital is a leading global alternative a
Takeda’s Zasocitinib Significantly Outperforms Deucravacitinib in Head-to-Head Phase 3 Psoriasis Study, Promising to Redefine Oral Treatment Expectations11.6.2026 14:00:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) announced positive topline results for the Phase 3, randomized, multicenter, double-blind study comparing zasocitinib (TAK-279), an investigational, next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, to deucravacitinib in adults with moderate-to-severe plaque psoriasis (PsO). In the LATITUDE Atlas (TAK-279-PsO-3004) head-to-head study, zasocitinib demonstrated statistical superiority over deucravacitinib for the primary endpoint, Psoriasis Area and Severity Index (PASI) 100 response rate at week 16. The study also demonstrated statistical superiority over deucravacitinib for all key secondary endpoints, including PASI 90 response and Static Physician's Global Assessment (sPGA) 0 at week 16. Zasocitinib was generally well tolerated with a consistent safety and tolerability profile and no new safety signals identified. Perspectives on head-to-head zasocitinib study “In this head-to-head study, zasocitinib clearly demonstrated
L&T Technology Services, Databricks Partner to Deliver Industrial AI at Scale for Asset-Intensive Industries11.6.2026 13:30:00 EEST | Press release
L&T Technology Services (BSE: 540115, NSE: LTTS), a global leader in AI, Digital & ER&D Consulting Services, today announced a strategic go-to-market partnership with Databricks, the leading Data and AI company, to co-develop and deliver Industrial AI solutions that advance Engineering Intelligence (EI) for asset-intensive enterprises. Anchored in LTTS' Sustainability segment, spanning Process Engineering, Discrete Manufacturing and Industrial Products, the partnership will support Energy, Petrochemicals and Industrials clients globally. As industrial organizations seek to unlock greater value from decades of operational and engineering data, the alliance will combine LTTS’ deep domain capabilities with the Databricks platform to transform complex plant data into Engineering Intelligence - enabling improved asset reliability, operational efficiency and sustainability performance. The partnership brings together LTTS’ expertise in forward looking technologies and extensive experience ac
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom